These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434 [TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Gale RP; Horowitz MM Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646 [TBL] [Abstract][Full Text] [Related]
4. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S Clin Transpl; 1996; ():281-90. PubMed ID: 9286578 [TBL] [Abstract][Full Text] [Related]
7. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394 [TBL] [Abstract][Full Text] [Related]
8. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience. Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585 [TBL] [Abstract][Full Text] [Related]
9. Ocular manifestations of graft versus host disease following bone marrow transplantation. Claes K; Kestelyn P Bull Soc Belge Ophtalmol; 2000; (277):21-6. PubMed ID: 11126670 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J; Ringdén O Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [TBL] [Abstract][Full Text] [Related]
11. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473 [TBL] [Abstract][Full Text] [Related]
12. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946 [TBL] [Abstract][Full Text] [Related]
13. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057 [TBL] [Abstract][Full Text] [Related]
14. Ocular involvement in chronic graft-versus-host disease: therapeutic approaches to complicated courses. Koch KR; Joussen AM; Huber KK Cornea; 2011 Jan; 30(1):107-13. PubMed ID: 20847653 [TBL] [Abstract][Full Text] [Related]
15. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report. Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598 [TBL] [Abstract][Full Text] [Related]
18. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Matsue K; Tabayashi T; Yamada K; Takeuchi M Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146 [TBL] [Abstract][Full Text] [Related]
19. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846 [TBL] [Abstract][Full Text] [Related]
20. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia]. Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]